Key facts
- Montara Therapeutics’s last known valuation is $55.0M (Feb 2025).
- It has raised $28.0M across 2 recorded rounds; the latest was Early Stage VC ($20.0M) in Feb 2025.
- Notable investors include Dolby Family Ventures, SV Health Investors, Bayshore Global Management, BEVC (Berkeley), KdT Ventures — 8 tracked in total.
- Montara Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently Mar 2025 ($20.0M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Montara Therapeutics
Funding rounds
2 roundsAbout Montara Therapeutics
Operator of a biopharmaceutical company intended to enhance the safety and efficacy of treatments for neurological diseases. The company specializes in brain-specific pharmacology by leveraging human genetics and machine learning to identify and validate drug targets, enabling medical professionals to develop therapies for previously undruggable targets and improving treatment outcomes for patients with neurological conditions.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Employees
- 21
- Website
- montaratx.com/
- Ownership
- Privately Held (backing)
Montara Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Montara Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Montara Therapeutics in its N-PORT filings yet. We sweep new filings monthly.